Genomes and Genes
Summary: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
Publications232 found, 100 shown here
- First-line therapies for lowering triglyceride levelsVasudevan A Raghavan
Am Fam Physician 77:416; author reply 417-8. 2008
- Extended-release niacin or ezetimibe and carotid intima-media thicknessAllen J Taylor
Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA
N Engl J Med 361:2113-22. 2009....
- Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitorsM John Chapman
INSERM, UMR S939, Dyslipidemia, Inflammation and Atherosclerosis Research Unit, University Pierre and Marie Curie Paris 6, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, Paris Cedex 13, France
Eur Heart J 31:149-64. 2010..e. statins, fibrates, and niacin, and compares their mechanisms of action with those of pharmacological agents under development which directly ..
- Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapySajoscha A Sorrentino
Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany
Circulation 121:110-22. 2010..Moreover, in diabetic patients, we examined the impact of extended-release (ER) niacin therapy on the endothelial effects of HDL.
- Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injurySuresh Varma Penumathsa
Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1110, USA
Biochim Biophys Acta 1792:39-48. 2009..We investigated the effect of niacin-bound chromium (NBC) during ischemia/reperfusion (IR) injury in streptozotocin induced diabetic rats...
- Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapibLaurent Yvan-Charvet
Division of Molecular Medicine, Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA
Arterioscler Thromb Vasc Biol 30:1430-8. 2010To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor-mediated ..
- Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging studyJustin M S Lee
Department of Cardiovascular Medicine, University of Oxford and Oxford Centre for Clinical Magnetic Resonance Research OCMR, Oxford, United Kingdom
J Am Coll Cardiol 54:1787-94. 2009..Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function...
- Molecular identification of high and low affinity receptors for nicotinic acidAlan Wise
Department of 7TMR Systems Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
J Biol Chem 278:9869-74. 2003..The discovery of HM74A as a molecular target for nicotinic acid may facilitate the discovery of superior drug molecules to treat dyslipidemia...
- Langerhans cells release prostaglandin D2 in response to nicotinic acidDominique Maciejewski-Lenoir
Arena Pharmaceuticals Inc, San Diego, California 92121, USA
J Invest Dermatol 126:2637-46. 2006..These results suggest that nicotinic acid mediates its flushing side effect by interacting with GPR109A on skin Langerhans cells, resulting in release of PGD(2)...
- Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbitsShui Ping Zhao
Department of Cardiology, The Second Xiangya Hospital of Central South University, Middle Ren Min Road No 86, Changsha, Hunan 410011, PR China
Int J Cardiol 124:172-8. 2008..The aim of this study was to evaluate the effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes from hypercholesterolemic ..
- Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemiaKlaus G Parhofer
Medical Department II Grosshadern, University of Munich, Germany
Vasc Health Risk Manag 5:901-8. 2009..b>Niacin (nicotinic acid) is an effective drug which increases the plasma concentration of high-density lipoprotein (HDL)-..
- beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in miceRobert W Walters
Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
J Clin Invest 119:1312-21. 2009..Furthermore, G protein-biased ligands that activate GPR109A in a beta-arrestin-independent fashion may represent an improved therapeutic option for the treatment of dyslipidemia...
- Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flushC Daniel Meyers
Long Beach Veterans Affairs Healthcare System, Long Beach, CA, United States
Atherosclerosis 192:253-8. 2007..shown to prevent cardiovascular disease, yet its widespread use is limited by the prostaglandin D2 (PGD2) mediated niacin flush...
- Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipidsBen J Wu
Lipid Research Group, Heart Research Institute, 7 Eliza St, Newtown, New South Wales, Australia 2042
Arterioscler Thromb Vasc Biol 30:968-75. 2010To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels.
- Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery diseaseJasleen K Duggal
Chicago Medical School and Affiliated Hospitals, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
J Cardiovasc Pharmacol Ther 15:158-66. 2010b>Niacin or nicotinic acid (vitamin B3) raises the levels of high-density lipoprotein cholesterol (HDL) by about 30% to 35%...
- Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2Allen J Taylor
Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Avenue, NW, Building 2, Room 4A34, Washington, DC 20307 5001, USA
Vasc Health Risk Manag 3:159-64. 2007We previously reported in a placebo-controlled study that extended-release niacin slowed the progression of carotid atherosclerosis when added to statin monotherapy...
- Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemiaS Shah
Merck Research Laboratories, Cardiovascular Disease, Merck, Sharp and Dohme Corp, Rahway, NJ 07065, USA
Int J Clin Pract 64:727-38. 2010Co-administration of niacin with statin offers the potential for additional lipid management and cardiovascular risk reduction...
- Safety and toxicological evaluation of a novel niacin-bound chromium (III) complexMichael Shara
Creighton University Medical Center, Omaha, NE, USA
J Inorg Biochem 99:2161-83. 2005..It also helps in energy production and increasing lean body mass. Niacin-bound chromium (NBC) is a unique form of bioavailable chromium that promotes healthy lipid profile...
- Nicotinic acid: pharmacological effects and mechanisms of actionAndreas Gille
Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
Annu Rev Pharmacol Toxicol 48:79-106. 2008....
- Combined statin and niacin therapy remodels the high-density lipoprotein proteomePattie S Green
Department of Medicine, University of Washington, Seattle, WA, USA
Circulation 118:1259-67. 2008..We hypothesized that an intervention that increases HDL levels-combined statin and niacin therapy-might reverse these changes.
- Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patientsDaniela Muller
Franz Volhard Clinic, Department of Nephrology and Hypertension, Medical Faculty of the Charite, HELIOS Klinikum Berlin, Berlin, Germany
Clin J Am Soc Nephrol 2:1249-54. 2007..Adverse effects complicate the use of drugs that are prescribed for phosphate control in dialysis patients. Alternative treatment options are needed...
- Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjectsCrystal A Gadegbeku
Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
Am J Hypertens 16:67-71. 2003..The adjustment in vascular compliance may be an important factor in determining overall BP response to NA...
- Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statinsAllen J Taylor
Cardiovascular Research, Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Ave, NW, Bldg 2, Room 3L28, Washington, DC 20307 5001, USA
Circulation 110:3512-7. 2004b>Niacin reduces coronary heart disease morbidity and mortality when taken either alone or in combination with statins; however, the incremental impact of adding niacin to background statin therapy is unknown.
- Biochemical assessment of niacin deficiency among carcinoid cancer patientsGirish M Shah
Laboratory for Skin Cancer Research, CHUL Research Center (CHUQ, Faculty of Medicine, Laval University, Sainte-Foy, Quebec, Canada
Am J Gastroenterol 100:2307-14. 2005..fraction of tryptophan catabolism, which should be directed along a pathway that allows partial conversion to niacin; hence, increased diversion of tryptophan toward serotonin could cause variable degrees of niacin deficiency in ..
- Treatment with niacin lowers ADMASabine Westphal
Atherosclerosis 184:448-50. 2006
- Niacin and carcinogenesisJames B Kirkland
Department of Human Biology and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada
Nutr Cancer 46:110-8. 2003The dietary status of niacin (vitamin B3) has the potential to influence DNA repair, genomic stability, and the immune system, eventually having an impact on cancer risk, as well as the side effects of chemotherapy in the cancer patient...
- Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levelsDavid M Capuzzi
Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Am J Cardiol 91:1304-10. 2003..and low high-density lipoprotein (HDL) cholesterol levels may benefit from combination therapy with a statin and niacin; therefore, we assessed the efficacy and safety of rosuvastatin and extended-release (ER) niacin alone and in ..
- Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary eventsMichael H Davidson
Department of Preventive Cardiology, Rush-Presbyterian-St. Luke's Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
Curr Atheroscler Rep 5:418-22. 2003
- Decreasing the oxidant stress from paraquat in isolated perfused rat lung using captopril and niacinMahmoud Ghazi-Khansari
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P O Box 13145 784, Tehran, Iran
Arch Toxicol 79:341-5. 2005The abilities of captopril and niacin to protect against the lung toxicity of paraquat (PQ) were studied...
- Clinical inquiries. Should liver enzymes be checked in a patient taking niacin?Gloria S Rizakallah
St Louis College of Pharmacy and Mercy Family Medicine, St Louis, MO USA
J Fam Pract 54:265-8. 2005
- Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonistsEster Carballo-Jane
Department of Pharmacology, Merck Research Laboratories, Rahway, NJ, USA
J Pharmacol Toxicol Methods 56:308-16. 2007..The rat and the dog have previously been used to study the antilipolytic effects of nicotinic acid, but no optimal vasodilatation model exits in either species...
- Effect of lipid-lowering drug therapy on small-dense low-density lipoproteinJames M Backes
Department of Pharmacy Practice, School of Pharmacy, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160 7231, USA
Ann Pharmacother 39:523-6. 2005..To review the effects of lipid-lowering therapy on small-dense low-density lipoprotein cholesterol (sdLDL-C)...
- Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic ratsSema Bolkent
Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, 34300-Cerrahpasa, Istanbul, Turkey
Biol Trace Elem Res 101:219-29. 2004Many studies have shown that niacin and Cr exert combined effects. Significant beneficial effects in serum lipid levels following Cr supplementation have been reported...
- Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complexMichael Shara
Creighton University Medical Center, Omaha, NE, USA
J Inorg Biochem 101:1059-69. 2007..including in vitro, in vivo and clinical studies demonstrated the beneficial effects of novel oxygen- coordinated niacin-bound chromium (III) complex (NBC) in promoting glucose-insulin sensitivity, lipid profile, cardioprotective ..
- Extended-release niacin for modifying the lipoprotein profileJohn R Guyton
Duke University Medical Center, Department of Medicine, Durham, North Carolina, USA
Expert Opin Pharmacother 5:1385-98. 2004b>Niacin (nicotinic acid) favourably modifies all aspects of the lipoprotein profile; it raises high-density lipoprotein cholesterol (HDL-C) levels, lowers triglyceride, low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) levels ..
- A topical lipophilic niacin derivative increases NAD, epidermal differentiation and barrier function in photodamaged skinElaine L Jacobson
Department of Pharmacology and Toxicology, College of Pharmacy, Tucson, AZ 85724, USA
Exp Dermatol 16:490-9. 2007....
- Niacin nutritional status in HIV type 1-positive children: preliminary dataMarina Hjertquist Tremeschin
Medical School of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil
J Pediatr Gastroenterol Nutr 44:629-33. 2007..This study compared the nutritional status and the 24-hour urine excretion of N-methylnicotinamide between HIV-positive children and HIV-negative children who were or were not born of mothers with HIV-1 infection...
- The effects of niacin on lipoprotein subclass distributionJohn M Morgan
Thomas Jefferson University, Jefferson Heart Institute, Sidney Kimmel Laboratory for Preventive Medicine, 925 Chestnut Street, 1st Floor, Philadelphia, PA 19107, USA
Prev Cardiol 7:182-7; quiz 188. 2004..b>Niacin has long been known to improve concentrations of all major lipids and lipoproteins, but it also has consistently ..
- Niacin therapy in atherosclerosisC Daniel Meyers
Endocrinology Section, VA Long Beach Healthcare System, Department of Medicine, University of California, Irvine, California, USA
Curr Opin Lipidol 15:659-65. 2004PURPOSE OF REVIEW: Well designed, randomized, placebo-controlled studies show that niacin prevents cardiovascular disease and death...
- Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failureKyu hyang Cho
Division of Nephrology and Hypertension, University of California, Irvine, California, USA
Am J Physiol Renal Physiol 297:F106-13. 2009..b>Niacin is known to improve lipid metabolism and exert antioxidant/anti-inflammatory actions...
- Protective effects of a novel niacin-bound chromium complex and a grape seed proanthocyanidin extract on advancing age and various aspects of syndrome XHarry G Preuss
Department of Physiology, Georgetown University Medical Center, Washington, D C 20007, USA
Ann N Y Acad Sci 957:250-9. 2002..Accordingly, ingestion of niacin-bound chromium and natural antioxidants such as grape seed proanthocyanidin extract has been demonstrated to ..
- Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjectsEseng Lai
Merck Research Laboratories, Rahway, NJ 07065, USA
Platelets 21:191-8. 2010Laropiprant (LRPT) has been shown to reduce flushing symptoms induced by niacin and has been combined with niacin for treatment of dyslipidemia...
- Niacin and laropiprantS Sanyal
Division of Cardiology, Department of Medicine, Preventive Cardiology Center, Tufts Medical Center, Boston, MA 02111, USA
Drugs Today (Barc) 46:371-8. 2010Nicotinic acid (niacin) is one of the oldest drugs used to treat dyslipidemia...
- Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular riskM John Chapman
Dyslipidemia, Inflammation and Atherosclerosis Research Unit, UMR S939, National Institute for Health and Medical Research INSERM, Hopital de la Pitie Salpetriere, Paris, France
Pharmacol Ther 126:314-45. 2010..In this context, there is renewed interest in pharmacotherapeutic strategies involving niacin and fibrates in monotherapy and in association with statins...
- Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal modelDean Papaliodis
Department of Pharmacology and Experimental Therapeutics, Molecular Immunopharmacology and Drug Discovery Laboratory, Tufts University School of Medicine, Tufts Medical Center, Boston, MA 02111, USA
J Pharmacol Exp Ther 327:665-72. 2008b>Niacin lowers serum cholesterol, low-density lipoprotein, and triglycerides, and it raises high-density lipoprotein. However, most patients experience cutaneous warmth and vasodilation (flush)...
- Does nicotinic acid (niacin) lower blood pressure?H E Bays
Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY40213, USA
Int J Clin Pract 63:151-9. 2009Nicotinic acid (niacin) is a well-established treatment for dyslipidaemia - an important cardiovascular disease (CVD) risk factor. However, niacin may also reduce blood pressure (BP), which is another important CVD risk factor...
- SIRT1 genetic variation and mortality in type 2 diabetes: interaction with smoking and dietary niacinM Carola Zillikens
Department of Internal Medicine, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
Free Radic Biol Med 46:836-41. 2009SIRT1 protects cells against oxidative stress and aging. Its activity may be modulated by dietary niacin (vitamin B3) intake...
- Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular diseaseDarbie Maccubbin
Merck Research Laboratories, Rahway, NJ, USA
Am J Cardiol 104:74-81. 2009b>Niacin has beneficial effects on a patient's lipid and lipoprotein profiles and cardiovascular risk, particularly at doses >2 g/day, but is underused due to flushing...
- Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patientsHarold E Bays
Louisville Metabolic and Atherosclerosis Research Center Inc, Louisville, Kentucky, USA
Clin Ther 31:115-22. 2009Dyslipidemia and high blood pressure are both major cardiovascular disease risk factors. Niacin is an effective lipid-altering agent that has been reported to reduce the risk of cardiovascular disease...
- Nicotinic acid and the prevention of coronary artery diseaseJanet E Digby
Department of Cardiovascular Medicine, University of Oxford, Oxford, UK
Curr Opin Lipidol 20:321-6. 2009..at all levels of LDL cholesterol has, therefore, given renewed emphasis on the therapeutic potential of niacin. The purpose of this review is to evaluate advances in the elucidation of mechanisms by which nicotinic acid ..
- Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mgJin Wi
Cardiology Division, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
Atherosclerosis 213:235-40. 2010..However, an optimal pharmacologic approach has not yet been established. The aim of this study is to compare the efficacy and tolerability of the typical doses of fenofibrate and niacin.
- High-affinity transporters for NAD+ precursors in Candida glabrata are regulated by Hst1 and induced in response to niacin limitationBiao Ma
Department of Molecular Biology and Genetics, Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 2185, USA
Mol Cell Biol 29:4067-79. 2009..C. glabrata is a NAD(+) auxotroph, and its growth depends on the availability of niacin (environmental vitamin precursors of NAD(+))...
- Niacin status and treatment-related leukemogenesisJames B Kirkland
University of Guelph, Guelph, Ontario, Canada, N1G 2W1
Mol Cancer Ther 8:725-32. 2009..b>Niacin deficiency, which is common in cancer patients, causes dramatic genomic instability in bone marrow cells in an in ..
- Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic ratsN Niu
Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China
Mol Biol Rep 36:1275-81. 2009Combined treatment with niacin and chromium has been found to have a protective effect against oxidative damage to different tissues of hyperlipidemic rats. But its effects on vascular endothelial dysfunction are less clear...
- Niacin's role in the statin eraErica L Brooks
Preventive Cardiology Center, Tufts Medical Center, Division of Cardiology, Department of Medicine, 800 Washington Street, Box 80, Boston, MA 02111, USA
Expert Opin Pharmacother 11:2291-300. 2010The combination use of niacin and HMG Co-A reductases (statins) is increasing. While statin therapy reduces the risk of adverse cardiovascular events, additional therapies are needed to decrease event rates further...
- Seeing red: flushing out instigators of niacin-associated skin toxicityRichard L Dunbar
Department of Medicine, Division of Experimental Therapeutics, Institute for Translational Medicine and Therapeutics, Pennsylvania 19104, USA
J Clin Invest 120:2651-5. 2010The use of niacin to improve plasma lipid levels and reduce risk of myocardial infarction is limited by noxious skin effects that result from stimulation of G protein-coupled receptor 109A (GPR109A) in skin immune cells...
- Postprandial triglyceride responses to aerobic exercise and extended-release niacinEric P Plaisance
Department of Kinesiology, Auburn University, Auburn, AL, USA
Am J Clin Nutr 88:30-7. 2008Aerobic exercise and niacin are frequently used strategies for reducing serum triglycerides, and, yet, there is no information regarding the combined effects of these strategies on postprandial triglycerides.
- Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular diseaseAnders G Olsson
Department of Medicine and Health, Linkoping University, SE 58183 Linkoping, Sweden
Expert Opin Pharmacother 11:1715-26. 2010..The best drug available for that purpose is niacin. In addition to increasing HDL cholesterol and apolipoprotein A1, niacin decreases triglycerides, low-density ..
- Niacin treatment of stroke increases synaptic plasticity and axon growth in ratsXu Cui
Department of Neurology, Henry Ford Hospital, Detroit, Mich 48202, USA
Stroke 41:2044-9. 2010b>Niacin is the most effective medication in current clinical use for increasing high-density lipoprotein cholesterol...
- Hypophosphatemic effect of niacin in patients without renal failure: a randomized trialDarbie Maccubbin
Rhode Island Hospital, Division of Kidney Diseases and Hypertension, 593 Eddy Street, Providence, RI, 02903, USA
Clin J Am Soc Nephrol 5:582-9. 2010b>Niacin administration lowers the marked hyperphosphatemia that is characteristic of renal failure...
- The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3Allen J Taylor
Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
Curr Med Res Opin 22:2243-50. 2006The ARBITER 2 trial showed that extended-release niacin (ERN) when added to statin monotherapy slowed the progression of carotid atherosclerosis over 12 months...
- Negative correlation between cerebral inorganic phosphate and the volumetric niacin response in male patients with schizophrenia who have seriously and dangerously violently offended: a (31)P magnetic resonance spectroscopy studyB K Puri
MRI Unit, Imaging Sciences Department, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London, UK
Prostaglandins Leukot Essent Fatty Acids 77:97-9. 2007..Spectra were obtained from 70 x 70 x 70 mm(3) voxels using an image-selected in vivo spectroscopy pulse sequence. Niacin flush testing results were quantified as the volumetric niacin response...
- Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)Paul L Canner
Maryland Medical Research Institute, Baltimore, Maryland, USA
Am J Cardiol 97:477-9. 2006This post hoc analysis from the Coronary Drug Project (CDP) evaluated the effects of niacin monotherapy on clinical outcomes in patients with and without the metabolic syndrome (MS)...
- Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose toleranceAxel Linke
Department of Cardiology, Heart Center, University of Leipzig, Leipzig, Germany
Atherosclerosis 205:207-13. 2009..Extended-release (ER) niacin increases HDL-C and was shown to slow the progression of atherosclerosis...
- 2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatmentZachary T Bloomgarden
Division of Endocrinology, Mount Sinai School of Medicine, New York, NY, USA
Diabetes Care 28:2795-802. 2005
- Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndromeRichard W Nesto
Department of Cardiovascular Medicine, Lahey Clinic, Burlington, Massachusetts 02493, USA
Am J Cardiovasc Drugs 5:379-87. 2005....
- Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?John J P Kastelein
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Am J Cardiol 96:20K-27K; discussion 34K-35K. 2005..Management of the metabolic syndrome focusing on the modification of plasma LDL as well as high-density lipoprotein cholesterol is reviewed. Future management strategies with the use of novel combination therapy is also discussed...
- Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular eventsEbrahim A Balbisi
Department of Clinical Pharmacy Practice, College of Pharmacy and Allied Health Professions, St John s University, New York, NY, USA
Med Sci Monit 12:RA34-9. 2006..In spite of the challenges, there are ample opportunities for improving the management of hyperlipidemia. Adherence to the recommendations will vastly reduce morbidity and mortality associated with CHD...
- Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacinJoanne LaFleur
Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, 84108, USA
Ann Pharmacother 40:1274-9. 2006..A fixed-dose combination product, extended-release niacin/lovastatin (ERNL), has been shown to be beneficial in lipid management; however, little is known regarding patient ..
- Nicotinic acid and other therapies for raising high-density lipoproteinLars A Carlson
Karolinska Institutet, King Gustaf V Research Institute, Stockholm, Sweden
Curr Opin Cardiol 21:336-44. 2006..Other treatments for raising high-density lipoprotein, including changes in lifestyle, other drugs and infusions of 'synthetic' (reconstituted) high-density lipoprotein will be summarized...
- Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterolSteven G Chrysant
Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma School of Medicine, Oklahoma City, 73132 4904, USA
J Clin Hypertens (Greenwich) 8:493-9; quiz 500-1. 2006..b>Niacin, on the other hand, is the most potent drug available for lowering plasma levels of triglycerides and lipoprotein(..
- [Treatment of dyslipidemia: how and when to combine lipid lowering drugs]Isio Schulz
Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP
Arq Bras Endocrinol Metabol 50:344-59. 2006..Association of statin/niacin seems be very useful in patients with FCH, especially as niacin is the best drug to increase HDL cholesterol; this ..
- Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemiaJohn F Paolini
Merck Research Laboratories, Rahway, NJ, USA
Am J Cardiol 101:625-30. 2008b>Niacin (nicotinic acid) is not optimally used mainly because of flushing, a process mediated primarily by prostaglandin D(2), which leads to poor patient compliance and suboptimal dosing...
- [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]Marlena Broncel
Department of Internal Diseases with Clinical Pharmacology and Therapy Monitoring Unit, Medical University of Łódź, Poland
Pol Merkur Lekarski 22:62-5. 2007..In this article, we briefly review the clinical trial data on the efficacy, safety and influence on non-lipid atherosclerosis factors of combined therapy statin with fibrates, statin with nicotinic acid and statin with ezetimibe...
- [When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis]M Farnier
Point Medical, Rond Point de la Nation, 21000 Dijon
Arch Mal Coeur Vaiss 100:569-81. 2007
- Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteinsStefania Lamon-Fava
Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA
Arterioscler Thromb Vasc Biol 28:1672-8. 2008Extended-release niacin effectively lowers plasma TG levels and raises plasma high-density lipoprotein (HDL) cholesterol levels, but the mechanisms responsible for these effects are unclear.
- Management of hyperlipidemia with statins in the older patientWilbert S Aronow
Department of Medicine, Cardiology and Geriatrics Divisions, New York Medical College, Valhalla, NY 10595, USA
Clin Interv Aging 1:433-8. 2006..When LDL cholesterol-lowering drug therapy is used to treat high-risk persons or moderately high-risk persons, the serum LDL cholesterol should be decreased at least 30% to 40%...
- Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomesMadiha Abdel-Maksoud
Department of Public Health, Preventive, and Social Medicine, Tanta University, Egypt
J Cardiovasc Pharmacol 51:331-51. 2008..However, randomized clinical trials involving fibrates have not shown consistent benefit. Niacin (nicotinic acid), which is the most effective available medication for raising HDL-C and also lowers triglycerides,..
- Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS studyRichard H Karas
Division of Cardiology, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA
Am J Cardiovasc Drugs 8:69-81. 2008..This fact has focused increased attention on treating abnormalities of non-high-density lipoprotein-cholesterol (non-HDL-C), HDL-C, and triglycerides in national guidelines and has intensified interest in combination therapy...
- Treatment of high-risk older persons with lipid-lowering drug therapyWilbert S Aronow
Department of Medicine, Divisions of Cardiology, Geriatrics, and Pulmonary Critical Care, New York Medical College, Valhalla, NY 10595, USA
Am J Ther 15:102-7. 2008..High-risk older persons should be treated with lipid-lowering drugs according to the NCEP III updated guidelines to reduce cardiovascular morbidity and mortality...
- Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapyTamar S Polonsky
University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637 1470, USA
Am J Cardiol 101:27B-35B. 2008..In this article, the authors review the use of combination therapy as a strategy for risk reduction in CAD...
- Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspectiveS Roze
CORE Center for Outcomes Research, IMS Health, Allschwil, Switzerland
Int J Clin Pract 61:1805-11. 2007..To evaluate the cost-effectiveness of raising high-density lipoprotein cholesterol (HDL-C) with add-on nicotinic acid in statin-treated patients with coronary heart disease (CHD) and low HDL-C, from the French healthcare system perspective...
- Treating hypertriglyceridemiaBruce J Holub
CMAJ 177:604; author reply 604-5. 2007
- Treating hypertriglyceridemiaGeorg Roggla
CMAJ 177:603; author reply 604-5. 2007
- Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system)Alawi A Alsheikh Ali
Molecular Cardiology Research Institute and Division of Cardiology, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
Am J Cardiol 99:379-81. 2007..Current drug labeling warns of an increased risk of adverse events with statin and niacin combinations. These recommendations have been based solely on case reports...
- Hypertriglyceridemia: its etiology, effects and treatmentGeorge Yuan
Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ont
CMAJ 176:1113-20. 2007..We review the causes and classification of elevated triglyceride levels, the clinical manifestations of primary hypertriglyceridemia and the management of patients with elevated triglyceride levels...
- [Therapy of dyslipidemia in post-infarction: state of the art]M C Borgia
Dipartimento di Scienze Cliniche, Universita Sapienza, Roma, Italia
Clin Ter 158:523-32. 2007..The innovative therapeutic approach to hypercholesterolemia today is based on a double inhibition of cholesterol synthesis and absorption combining a statin with ezetimibe...
- Safety and tolerability of prolonged-release nicotinic acid in statin-treated patientsR S Birjmohun
Academic Medical Center, Amsterdam, The Netherlands
Curr Med Res Opin 23:1707-13. 2007..To evaluate the safety and tolerability of prolonged-release nicotinic acid (Niaspan) added to statin therapy in patients at increased cardiovascular risk...
- The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular diseaseEberhard Windler
Center of Internal Medicine, University Hospital Hamburg Eppendorf, Hamburg, Germany
Diab Vasc Dis Res 4:136-42. 2007....
- Managing dyslipidemia in chronic kidney diseaseCharles R Harper
Department of Medicine, Emory University, Atlanta, Georgia 30303, USA
J Am Coll Cardiol 51:2375-84. 2008..After reviewing the safety and dose alterations required in managing dyslipidemia in patients with CKD, a practical treatment algorithm is proposed...
- Clinical practice. HypertriglyceridemiaJohn D Brunzell
Department of Medicine, Division of Metabolism, Endocrinology, and Nutrition, and the Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle, USA
N Engl J Med 357:1009-17. 2007
- Treating hypertriglyceridemiaIrfan Yavasoglu
CMAJ 177:603-4; author reply 604-5. 2007
- Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemiaJohn R Guyton
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
J Am Coll Cardiol 51:1564-72. 2008This study evaluated the safety and lipid-altering efficacy of ezetimibe/simvastatin (E/S) coadministered with extended-release niacin (N) in patients with type IIa or IIb hyperlipidemia.
- Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?S Tavintharan
Department of Medicine, Alexandra Hospital, 378 Alexandra Road, Singapore 159964
Singapore Med J 46:519-28. 2005..A number of agents potentially modify HDL favourably. Niacin is the most potent HDL-C raising agent currently available in clinical practice, followed by fibrates...
- [Low HDL-cholesterol, high triglycerides--well known but often ignored]R Benz
Medizinische Poliklinik, Hypertonie und Adipositassprechstunde, Universitatsspital Zurich
Praxis (Bern 1994) 93:1911-6. 2004..We therefore want to show the relation of the triglyzerides with the HDL-Cholesterol and the nonpharmacologic treatment of these two factors. Some clinical examples are illustrating the topic...
- Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practiceR S Birjmohun
Department of Vascular Medicine, Academic Medical Centre, PO Box 22660, 1100 DD Amsterdam, The Netherlands
Neth J Med 62:229-34. 2004..The inverse relation between high-density lipoprotein cholesterol (HDL-C) and cardiovascular (CV) disease underscores the need for clinical evaluation of the effect of HDL-C increasing drugs on the prevalence of CV disease...
- Coadministration of multidrug therapy to achieve lipid goalsMargo A Denke
The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284, USA
J Am Osteopath Assoc 104:S17-22. 2004..The coadministration of low doses of these agents has been proved to be as effective as high-dose statin therapy in reducing LDL-C levels and assisting patients achieve their treatment goals...
- Existing and investigational combination drug therapy for high-density lipoprotein cholesterolHarold Bays
Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
Am J Cardiol 90:30K-43K. 2002..This more global, multidimensional approach to lipid-altering drug treatment may provide the best chance to prevent CAD...
- Utility of currently available modes of therapy in reaching lipid goalsKelly Anne Spratt
University of Pennsylvania Health System, Cardiovascular Division, Philadelphia Heart Institute, Second Floor, 39th and Market Streets, Philadelphia, PA 19104, USA
J Am Osteopath Assoc 104:S14-6. 2004..In addition, nonprescription agents such as plant stanols and sterols are available to modify plasma lipid levels. These agents can be used individually or coadministered to achieve lipid goals...
- Use of combination therapy for dyslipidemia: a lipid clinic approachAlan S Brown
Midwest Heart Specialists Disease Prevention Center, Naperville, Illinois 60540, USA
Am J Cardiol 90:44K-49K. 2002..Approaches to LDL lowering for complex dyslipidemias and management strategies for specific lipid-lowering therapies are provided...
- Combination therapy for dyslipidemia: safety and regulatory considerationsMichael H Davidson
Chicago Center for Clinical Research, Rush Medical College, Chicago, Illinois 60612, USA
Am J Cardiol 90:50K-60K. 2002..lipid-altering therapy often requires the use of combination therapy involving statins in conjunction with niacin, fibric-acid derivatives, ezetimibe, or bile acid resins...
- Effect of Extended-Release Niacin on Saphenous Vein Graft AtherosclerosisEmmanouil Brilakis; Fiscal Year: 2010..b>Niacin raises HDL-C, restores the re-endothelialization capacity of EPCs, and slowed the progression of SVG ..
- Aromatic amino acid metabolism in the pathogenesis of kwashiorkorFarook Jahoor; Fiscal Year: 2007..are precursors for dopamine, melanin and the catecholamines, and tryptophan is the precursor of serotonin and niacin, a shortage of the AAAs may underlie most of the signs and symptoms of kwashiorkor...
- LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPYDavid Hui; Fiscal Year: 2004..The potential beneficial effects of niacin, due to its proteasome-independent stimulation of apoB degradation, will also be explored...
- Discovery and Preclinical Development of Drugs for Anthrax, Plague and TularemiaChristie Brouillette; Fiscal Year: 2007..These diseases are caused by three of the highest risk bacterial bioterrorism agents, B. anthracis, Y. pestis, and F. tularensis. ..
- Comprehensive Magnetic Resonance in PADChristopher M Kramer; Fiscal Year: 2010..Aim 3 is to use comprehensive MR to test the efficacy of raising HDL with a novel formulation of niacin with laropiprant that reduces flushing compared to placebo in mild to moderate PAD...
- OMEGA-3 FATTY ACIDS IN BIPOLAR DISORDER PROPHYLAXISANDREW STOLL; Fiscal Year: 2002..Plasma and erythrocyte fatty acid content. 2. The niacin skin patch test (a possible marker of in vivo omega-3 fatty acid activity). 3...
- MECHANISMS OF ENZYMATIC REACTIONSPERRY FREY; Fiscal Year: 2002..in studies of Ga1E will be to describe the molecular basis for the enhancement of the chemical reactivity of the niacin- co-enzyme NAD+ by the use of binding energy between the UDP-moiety of substrates and the enzyme...
- HDL AND PLAQUES--NOVEL MODELS AND IMAGING TECHNIQUESEdward Fisher; Fiscal Year: 2001..Plasma lipid levels will be modified by therapy with a statin or statin plus niacin (to raise HDL) and changes in plaque size and composition will be followed serially by MRI...
- Niacin, n-3 fatty acids and insulin resistanceWilliam Harris; Fiscal Year: 2006..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
- Niacin, n-3 fatty acids and insulin resistanceWilliam Harris; Fiscal Year: 2007..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
- MODE OF ACTION OF PYRAZINAMIDE IN TUBERCLE BACILLUSYing Zhang; Fiscal Year: 2003..Because of structural similarity of POA to niacin, they hypothesize that POA may interfere with NAD metabolism in M...
- MODE OF ACTION OF PYRAZINAMIDE IN TUBERCLE BACILLUSYing Zhang; Fiscal Year: 1999..Because of structural similarity of POA to niacin, they hypothesize that POA may interfere with NAD metabolism in M...
- A Transdermal Hypolipidemic Niacin ProdrugHyuntae Kim; Fiscal Year: 2002b>Niacin has been used as first-line drug therapy for elevated serum cholesterol because of its broad efficacy on multiple lipid components as well as its low cost...
- A Trial of Zinc and Micronutrients in Tanzanian ChildrenChristopher P Duggan; Fiscal Year: 2010..be recruited and randomly assigned in a factorial design to either zinc, micronutrients (vitamins C, E, B1, B2, niacin, B6, folate, and B12) plus zinc, micronutrients without zinc, or a placebo given daily...
- Diet/Exercise, Niacin, Fenofibrate for HIV LipodystrophyAshok Balasubramanyam; Fiscal Year: 2007..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
- Diet/Exercise, Niacin, Fenofibrate for HIV LipodystrophyAshok Balasubramanyam; Fiscal Year: 2007..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
- A Trial of Zinc and Micronutrients in Tanzanian ChildrenChristopher Duggan; Fiscal Year: 2007..be recruited and randomly assigned in a factorial design to either zinc, micronutrients (vitamins C, E, B1, B2, niacin, B6, folate, and B12) plus zinc, micronutrients without zinc, or a placebo given daily...
- MECHANISMS OF ENZYMATIC REACTIONSPERRY FREY; Fiscal Year: 2006..of epimerase will be to elucidate the molecular basis for the enhancement of the chemical reactivity of the niacin-coenzyme NAD+ by the use of binding energy between substrates and the enzyme...
- Monitoring Oxygen Repeatedly for Hypoxic Tumor TherapyMohammad Khan; Fiscal Year: 2007..The proposed approach to modulate tumor hypoxia will avoid possible complications and toxicity arising due to oral or injections of drugs. If successful, this approach potentially could be immediately extended for clinical applications. ..